FDA Expands Access to Promising Pancreatic Cancer Drug daraxonrasib
The U.S. Food and Drug Administration has approved expanded access to daraxonrasib, a targeted pancreatic cancer drug developed by Revolution Medicines, according to The New York Times and Reuters. The decision opens the door for more patients awaiting treatment to receive a therapy that has demonstrated significant efficacy in clinical trials.
A Breakthrough Therapy
Daraxonrasib is a targeted inhibitor directed at the KRAS G12D mutation. KRAS mutations are among the most common driver alterations in pancreatic cancer, found in approximately 35% to 40% of pancreatic ductal adenocarcinoma cases. For decades, the KRAS protein was considered “undruggable” due to its structural characteristics, but a new generation of covalent inhibitors has changed that landscape.
Reuters reports that in early-stage clinical trials, daraxonrasib caused significant tumor shrinkage in some patients with advanced pancreatic cancer. Notably, the spouse of former Senator Ben Sasse has shown encouraging results on the drug, drawing widespread public attention.
What Expanded Access Means
The FDA’s expanded access program — also known as “compassionate use” — allows unapproved drugs to be used by patients with serious or life-threatening conditions who cannot enroll in clinical trials. The approval of this pathway means more patients who are ineligible for trial participation can gain early access to treatment.
The Washington Post notes that the speed of the expanded access approval reflects the FDA’s strong confidence in the drug’s efficacy data. While such approvals typically take several weeks, this one was processed in under two weeks.
The Challenge of Pancreatic Cancer
Pancreatic cancer is often called the “king of cancers” and ranks as the fourth leading cause of cancer-related death in the United States. Due to its subtle early symptoms, difficulty in detection, and limited treatment options, the five-year survival rate has long hovered around just 12%.
Revolution Medicines’ Chief Medical Officer stated: “We are pleased to work with the FDA to give more patients in desperate need the opportunity to receive daraxonrasib. This is an important step toward transforming the pancreatic cancer treatment landscape.”
Market Outlook
Industry analysts project that if daraxonrasib continues to demonstrate positive data in later-stage trials, it could receive full FDA approval by 2027. At that point, the KRAS-targeted therapy market is expected to reach tens of billions of dollars, covering indications in pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
Source: The New York Times · Reuters · USA Today